Good read_老虎社区_美港股上老虎

2021-04-27

Good read

5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称 5 只小盘股上涨空间为 60% 至 140%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":377581011,"tweetId":"377581011","gmtCreate":1619535680733,"gmtModify":1634211958870,"author":{"id":3580731839183444,"idStr":"3580731839183444","authorId":3580731839183444,"authorIdStr":"3580731839183444","name":"chantow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Good read</body></html>","htmlText":"<html><head></head><body>Good read</body></html>","text":"Good read","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/377581011","repostId":1112397012,"repostType":4,"repost":{"id":"1112397012","kind":"news","pubTimestamp":1619521537,"share":"https://www.laohu8.com/m/news/1112397012?lang=zh_CN&edition=full","pubTime":"2021-04-27 19:05","market":"us","language":"en","title":"5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称 5 只小盘股上涨空间为 60% 至 140%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1112397012","media":"Motley Fool","summary":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% ","content":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&amp;P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.<blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏。在 2020 年第一季度短短 33 个日历日内损失了 34% 的价值后，该基准标普500自 2020 年 3 月 23 日触及熊市底部以来，截至上周末，该股已大幅上涨 87%。</blockquote>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.<blockquote>尽管大盘股（市值至少为 100 亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值 3 亿至 20 亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或证明。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.<blockquote>根据华尔街分析师一致的一年价格目标，以下五只小盘股的上涨空间从 60% 到 140% 不等。</blockquote><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Vaxart: Implied upside of 140%<blockquote>Vaxart：隐含上涨空间为 140%</blockquote>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).<blockquote>有近2000只小盘股和证券供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难达到 140%瓦克萨特（纳斯达克股票代码：VXRT）</blockquote>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.<blockquote>Vaxart 白手起家的故事将归结为该公司的冠状病毒疾病 2019 (COVID-19) 治疗方案 VXA-CoV2-1 在临床研究中的表现。这种治疗方法的独特之处在于，它是一种片剂，而不是注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药。</blockquote>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.<blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中取得积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始菌株和变异菌株有效。</blockquote>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.<blockquote>现在判断 Vaxart 的口服 COVID-19 治疗是否会在中后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Harvest Health &amp; Recreation: Implied upside of 90%<blockquote>Harvest Health &amp; Recreation：隐含上涨空间 90%</blockquote>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health &amp; Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.<blockquote>由于大麻预计将成为本十年的主要增长趋势，美国多州运营商 (MSO) 被分配了 12 个月的高价目标也许并不奇怪丰收健康与娱乐（场外交易：HRVSF）。如果华尔街的目标价准确，Harvest Health 明年可能会上涨 90%。</blockquote>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.<blockquote>与大多数美国 MSO 不同，Harvest Health 在 2019 年的视野有点过于开阔，并且过度扩张。在终止了一些交易并筹集资金后，该公司现在有望在 2021 年实现全年销售额估计为 3.8 亿美元的潜在利润。就上下文而言，这意味着64%的隐含销售额增长。</blockquote>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.<blockquote>目前，该公司在五个州拥有 37 个运营零售点，核心重点是四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管佛罗里达州只对医用大麻合法，但它正在大赚一笔，而宾夕法尼亚州是一个许可证有限的州，这应该为该公司提供一定程度的竞争保护，因为它的目标是吞噬份额。但随着 15 家门店在其家乡亚利桑那州开业，大峡谷州代表了 Harvest Health 最大的机遇。</blockquote>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.<blockquote>尽管它必须向投资者证明它已经克服了早期的运营失误，但 Harvest Health 看起来有望在 2021 年迈向“绿色”。</blockquote><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>EverQuote: Implied upside of 83%<blockquote>EverQuote：隐含上涨空间为 83%</blockquote>Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.<blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商永恒报价（纳斯达克股票代码：EVER）根据 61.58 美元的一致目标价，如果分析师准确的话，EverQuote 明年的股价可能会上涨 83%。</blockquote>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.<blockquote>谈论任何与保险有关的事情通常都足以让人入睡。EverQuote旨在通过其在线市场改变这一现状，消费者可以快速轻松地从领先的保险提供商那里获得定价政策。据该公司称，五分之一的消费者最终在其平台上购买了保单，这表明其购物者往往是有动力的。换句话说，保险公司通过委托 EverQuote 的市场获得了更多的广告收入。</blockquote>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.<blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长 16%。相比之下，保险行业的总广告和分销支出（包括数字支出）预计到 2024 年每年仅增长 4%。EverQuote 正在迎合保险业增长的甜蜜点。</blockquote>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.<blockquote>这也是一家一直在向新的垂直领域过渡的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了家庭、租房、健康和人寿保险选项。这些新的垂直市场的增长速度比传统的汽车保单快得多。</blockquote><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Jushi Holdings: Implied upside of 60%<blockquote>巨石控股：隐含上涨空间60%</blockquote>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.<blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小型MSO巨石控股（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来 60% 的收益。</blockquote>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.<blockquote>Harvest Health专注于四个市场，而Jushi主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州开展业务，但这三家公司限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则根据管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州发展业务，同时面临最小的竞争。</blockquote>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.<blockquote>这家公司也不怕投入资金。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.<blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士贡献了首批 2.5 亿美元融资中的约 4500 万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Inovio Pharmaceuticals: Implied upside of 128%<blockquote>Inovio Pharmaceuticals：隐含上涨空间 128%</blockquote>Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.<blockquote>最后，临床阶段生物技术股票伊诺维奥制药公司（纳斯达克股票代码：INO）被认为具有显着的上涨空间。根据 12 个月目标价 15.63 美元计算，Inovio 的股价可能会翻一番以上。但这是我强烈不同意华尔街的一个例子。</blockquote>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.<blockquote>在过去一年的大部分时间里，Inovio 一直寄希望于它将成为开发 COVID-19 疫苗的领跑者之一。但是，尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床停滞。上周，该公司宣布其 INO-4800 治疗 COVID-19 的 3 期研究将在美国境外进行，美国国防部将停止资助该公司 INO-4800 的后期研究。</blockquote>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.<blockquote>这里实际上有两个问题。首先，由于美国食品药品监督管理局 (FDA) 的部分临床认定，Inovio 远远落后于同行，即使 INO-4800 在临床研究中取得成功，它也可能无法在全球 COVID-19 疫苗销售中占据有意义的份额。</blockquote>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.<blockquote>其次，四十多年过去了，Inovio 没有什么可以展示的。尽管正在进行大量研究，但该公司的实验性治疗方法从未获得 FDA 的批准。这是一个非常明显的危险信号。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称 5 只小盘股上涨空间为 60% 至 140%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Small-Cap Stocks With 60% to 140% Upside, According to Wall Street<blockquote>华尔街称 5 只小盘股上涨空间为 60% 至 140%</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nMotley Fool2021-04-27 19:05\n\n</h4>\n</header>\n<article>\nFor more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&amp;P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.<blockquote>一年多来，投资者一直被华尔街史诗般的反弹宠坏。在 2020 年第一季度短短 33 个日历日内损失了 34% 的价值后，该基准标普500自 2020 年 3 月 23 日触及熊市底部以来，截至上周末，该股已大幅上涨 87%。</blockquote>Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.<blockquote>尽管大盘股（市值至少为 100 亿美元的公司）一直是这次反弹的明星，但华尔街认为小盘股（市值 3 亿至 20 亿美元）已经准备好大放异彩。小盘股通常风险更大，因为它们的运营模式未经时间考验或证明。但与更成熟的公司相比，它们通常可以提供更好的增长前景。</blockquote>Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.<blockquote>根据华尔街分析师一致的一年价格目标，以下五只小盘股的上涨空间从 60% 到 140% 不等。</blockquote><img src=\"https://static.tigerbbs.com/e84aa34310d37f1ab30212f9dcf1bf0d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Vaxart: Implied upside of 140%<blockquote>Vaxart：隐含上涨空间为 140%</blockquote>There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).<blockquote>有近2000只小盘股和证券供投资者选择。然而，华尔街专业人士认为，明年临床阶段生物技术股票的潜在回报率将很难达到 140%瓦克萨特（纳斯达克股票代码：VXRT）</blockquote>The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.<blockquote>Vaxart 白手起家的故事将归结为该公司的冠状病毒疾病 2019 (COVID-19) 治疗方案 VXA-CoV2-1 在临床研究中的表现。这种治疗方法的独特之处在于，它是一种片剂，而不是注射，可以在克服疫苗耐药性和给药方面发挥关键作用。毕竟，你不需要训练有素的医务人员来给药。</blockquote>At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.<blockquote>2月初，Vaxart宣布VXA-CoV2-1在1期试验中取得积极的第一步。初步数据显示，它已达到所有主要和次要安全性和免疫原性终点。此外，有早期迹象表明它可能对新冠肺炎的原始菌株和变异菌株有效。</blockquote>It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.<blockquote>现在判断 Vaxart 的口服 COVID-19 治疗是否会在中后期试验中取得成功还为时过早，但如果有效，它肯定会提供改变游戏规则的潜力。</blockquote><img src=\"https://static.tigerbbs.com/9c2902426a62a08435f7d40bec78432d\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Harvest Health &amp; Recreation: Implied upside of 90%<blockquote>Harvest Health &amp; Recreation：隐含上涨空间 90%</blockquote>With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health &amp; Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.<blockquote>由于大麻预计将成为本十年的主要增长趋势，美国多州运营商 (MSO) 被分配了 12 个月的高价目标也许并不奇怪丰收健康与娱乐（场外交易：HRVSF）。如果华尔街的目标价准确，Harvest Health 明年可能会上涨 90%。</blockquote>Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.<blockquote>与大多数美国 MSO 不同，Harvest Health 在 2019 年的视野有点过于开阔，并且过度扩张。在终止了一些交易并筹集资金后，该公司现在有望在 2021 年实现全年销售额估计为 3.8 亿美元的潜在利润。就上下文而言，这意味着64%的隐含销售额增长。</blockquote>Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.<blockquote>目前，该公司在五个州拥有 37 个运营零售点，核心重点是四个市场：亚利桑那州、佛罗里达州、马里兰州和宾夕法尼亚州。尽管佛罗里达州只对医用大麻合法，但它正在大赚一笔，而宾夕法尼亚州是一个许可证有限的州，这应该为该公司提供一定程度的竞争保护，因为它的目标是吞噬份额。但随着 15 家门店在其家乡亚利桑那州开业，大峡谷州代表了 Harvest Health 最大的机遇。</blockquote>Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.<blockquote>尽管它必须向投资者证明它已经克服了早期的运营失误，但 Harvest Health 看起来有望在 2021 年迈向“绿色”。</blockquote><img src=\"https://static.tigerbbs.com/c13ce819ae0ba9b6755b8d61f6584bbc\" tg-width=\"700\" tg-height=\"439\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>EverQuote: Implied upside of 83%<blockquote>EverQuote：隐含上涨空间为 83%</blockquote>Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.<blockquote>另一只具有巨大上涨潜力的小盘股是在线保险市场提供商永恒报价（纳斯达克股票代码：EVER）根据 61.58 美元的一致目标价，如果分析师准确的话，EverQuote 明年的股价可能会上涨 83%。</blockquote>Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.<blockquote>谈论任何与保险有关的事情通常都足以让人入睡。EverQuote旨在通过其在线市场改变这一现状，消费者可以快速轻松地从领先的保险提供商那里获得定价政策。据该公司称，五分之一的消费者最终在其平台上购买了保单，这表明其购物者往往是有动力的。换句话说，保险公司通过委托 EverQuote 的市场获得了更多的广告收入。</blockquote>According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.<blockquote>据该公司称，未来四年数字保险广告支出预计将每年增长 16%。相比之下，保险行业的总广告和分销支出（包括数字支出）预计到 2024 年每年仅增长 4%。EverQuote 正在迎合保险业增长的甜蜜点。</blockquote>It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.<blockquote>这也是一家一直在向新的垂直领域过渡的公司。尽管汽车保险一直是其市场的支柱，但近年来它增加了家庭、租房、健康和人寿保险选项。这些新的垂直市场的增长速度比传统的汽车保单快得多。</blockquote><img src=\"https://static.tigerbbs.com/f46d76c781cc47d68033914c1c794a63\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Jushi Holdings: Implied upside of 60%<blockquote>巨石控股：隐含上涨空间60%</blockquote>Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.<blockquote>以防你第一次没有抓住重点，华尔街对未来12个月的大多数美国大麻股票非常乐观。小型MSO巨石控股（场外交易代码：JUSHF）也不例外。如果巨石确实达到华尔街的目标价，它将为股东带来 60% 的收益。</blockquote>Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.<blockquote>Harvest Health专注于四个市场，而Jushi主要专注于三个市场：宾夕法尼亚州、伊利诺伊州和弗吉尼亚州。尽管它在大约六个州开展业务，但这三家公司限制了它分配零售许可证的方式。宾夕法尼亚州和伊利诺伊州限制了允许的药房数量，而弗吉尼亚州则根据管辖区分配许可证。结论是，巨石将有一个坚实的机会在这些州发展业务，同时面临最小的竞争。</blockquote>This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.<blockquote>这家公司也不怕投入资金。自今年年初以来，该公司进行了一系列收购，包括扩大其在马萨诸塞州、俄亥俄州、宾夕法尼亚州和加利福尼亚州的零售或种植足迹。</blockquote>If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.<blockquote>如果您正在寻找另一个催化剂，请考虑一下高管和内部人士贡献了首批 2.5 亿美元融资中的约 4500 万美元。当内部人士和股东的利益一致时，我们经常会看到好事发生。</blockquote><img src=\"https://static.tigerbbs.com/b9ff45f54cb49bde34240fc05af21a38\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><blockquote></blockquote>IMAGE SOURCE: GETTY IMAGES.<blockquote>图片来源：盖蒂图片社。</blockquote>Inovio Pharmaceuticals: Implied upside of 128%<blockquote>Inovio Pharmaceuticals：隐含上涨空间 128%</blockquote>Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.<blockquote>最后，临床阶段生物技术股票伊诺维奥制药公司（纳斯达克股票代码：INO）被认为具有显着的上涨空间。根据 12 个月目标价 15.63 美元计算，Inovio 的股价可能会翻一番以上。但这是我强烈不同意华尔街的一个例子。</blockquote>For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.<blockquote>在过去一年的大部分时间里，Inovio 一直寄希望于它将成为开发 COVID-19 疫苗的领跑者之一。但是，尽管通过了1期研究，Inovio在美国的2/3期试验中遇到了部分临床停滞。上周，该公司宣布其 INO-4800 治疗 COVID-19 的 3 期研究将在美国境外进行，美国国防部将停止资助该公司 INO-4800 的后期研究。</blockquote>There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.<blockquote>这里实际上有两个问题。首先，由于美国食品药品监督管理局 (FDA) 的部分临床认定，Inovio 远远落后于同行，即使 INO-4800 在临床研究中取得成功，它也可能无法在全球 COVID-19 疫苗销售中占据有意义的份额。</blockquote>Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.<blockquote>其次，四十多年过去了，Inovio 没有什么可以展示的。尽管正在进行大量研究，但该公司的实验性治疗方法从未获得 FDA 的批准。这是一个非常明显的危险信号。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/\">Motley Fool</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/27/5-small-cap-stocks-60-to-140-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1112397012","content_text":"For more than a year, investors have been spoiled by an epic rally on Wall Street. After losing 34% of its value in a span of just 33 calendar days in the first quarter of 2020, the benchmarkS&P 500has roared back to gain 87% since hitting its bear-market bottom on March 23, 2020, through this past weekend.Though large-cap stocks (companies with market caps of at least $10 billion) have been the stars of this rally, it'ssmall-cap stocks($300 million to $2 billion market cap) that Wall Street believes are ready to shine. Small-caps are typically riskier in that their operating models aren't time-tested or proven. But they can usually deliver superior growth prospects compared to more mature companies.Based on the consensus one-year price targets of Wall Street analysts, the following five small-cap stocks all offer upside ranging from 60% to as much as 140%.IMAGE SOURCE: GETTY IMAGES.Vaxart: Implied upside of 140%There are close to 2,000 small-cap stocks and securities for investors to choose from. However, Wall Street professionals believe you'll have a hard time topping thepotential 140% return over the next yearfrom clinical-stage biotech stockVaxart(NASDAQ:VXRT).The Vaxart rags-to-riches story will come down to how well the company's coronavirus disease 2019 (COVID-19) treatment option, VXA-CoV2-1, fares in clinical studies. What makes this treatment so unique is that it's a tablet, rather than a shot, which could play a key role in overcoming vaccine resistance and administration. After all, you don't need trained medical personnel to administer to a tablet.At the beginning of February, Vaxart announced a positive first step for VXA-CoV2-1 in a phase 1 trial. Preliminary data showed it had reached all of its primary and secondary safety and immunogenicity endpoints. Plus, there were early signs it could be effective against the original and variant strains of COVID-19.It'sfar too early to tellif Vaxart's oral COVID-19 treatment will be a success in mid-or-late-stage trials, but it certainly offers game-changing potential if it is effective.IMAGE SOURCE: GETTY IMAGES.Harvest Health & Recreation: Implied upside of 90%With cannabis expected to be a major growth trend this decade, perhaps it's no surprise to find a lofty 12-month price target assigned to U.S. multistate operator (MSO)Harvest Health & Recreation(OTC:HRVSF). If Wall Street's price target is accurate, Harvest Health could gain 90% over the next year.Unlike most U.S. MSOs, Harvest Health was a bit too wide-eyed in 2019 and overextended itself. After terminating a handful of deals and raising capital, the company is nowon trackto potentially eke out a profit in 2021 on an estimated $380 million in full-year sales. For context, this represents implied sales growth of 64%.Currently, the company has 37 operational retail locations in five states, with a core focus on four markets: Arizona, Florida, Maryland, and Pennsylvania. Florida is raking in big bucks despite only being legal for medical marijuana, while Pennsylvania is a limited license state, which should provide some degree of competitive protection for the company as it aims to gobble up share. But with15 stores open its home state of Arizona, the Grand Canyon State represents Harvest Health's greatest opportunity.Though it'll have to prove to investors that it's overcome its early operating missteps, Harvest Health looks to be on its way to \"going green\" in 2021.IMAGE SOURCE: GETTY IMAGES.EverQuote: Implied upside of 83%Another small-cap stock with serious upside potential is online insurance marketplace providerEverQuote(NASDAQ:EVER). Based on a consensus price target of $61.58, EverQuote could gain up to 83% over the next year, if analysts are accurate.Talking about anything having to do with insurance is usually enough to put people to sleep. EverQuote aims to change that with its online marketplace where consumers can quickly and easily get price policies from leading insurance providers. According to the company, 1 in 5 consumers ends up purchasing a policy on its platform, which demonstrates that its shoppers tend to be motivated. In other words, insurers are getting more bang for their advertising buck by entrusting EverQuote's marketplace.According to the company, digital insurance ad spending isexpected to grow by 16% annuallyover the next four years. By comparison, total ad and distribution spending for the insurance industry, including digital spending, is only forecast to grow by 4% annually through 2024. EverQuote is catering to the sweet spot of insurance industry growth.It's also a company that'sbeen transitioning to new verticals. Even though auto insurance has always been its marketplace bread-and-butter, it's added home, renters, health, and life insurance options in recent years. These new verticals are growing at a much faster clip than traditional auto policies.IMAGE SOURCE: GETTY IMAGES.Jushi Holdings: Implied upside of 60%Just in case you didn't catch the emphasis the first time around, Wall Street is really upbeat on most U.S.marijuana stocksover the next 12 months. Small-cap MSOJushi Holdings(OTC:JUSHF)is no exception. If Jushi does hit Wall Street's price target, it'll be rewarding its shareholders with a gain of 60%.Whereas Harvest Health is focusing on four markets, Jushi isprimarily honed in on three: Pennsylvania, Illinois, and Virginia. Though it has a presence in around a half-dozen states, this trio limits how it assigns retail licenses. Pennsylvania and Illinois have capped the number of allowed dispensaries, whereas Virginia assigns licenses by jurisdiction. The takeaway is that Jushi is going to have a solid opportunity to build up its business in these states while facing minimal competition.This is a company that hasn't been afraid to put its capital to work, either. It's made a host of acquisitions since the year began, including expanding its retail or cultivation footprint in Massachusetts, Ohio, Pennsylvania, and California.If you're looking for one more catalyst, consider that executives and insiders contributed approximately $45 million of the first $250 million in capital raised. When the interests of insiders and shareholders align, we often see good things happen.IMAGE SOURCE: GETTY IMAGES.Inovio Pharmaceuticals: Implied upside of 128%Finally, clinical-stagebiotech stockInovio Pharmaceuticals(NASDAQ:INO)is believed to offer significant upside. Based on a 12-month price target of $15.63, Inovio's shares could more than double. But this one instance where I strongly disagree with Wall Street.For much of the past year, Inovio has flown higher on the expectation that it would be among the frontrunners to develop a COVID-19 vaccine. But despite flying though phase 1 studies, Inovio encountered a partial clinical hold in phase 2/3 trials in the United States. This past week, the company announced that its phase 3 study for INO-4800 as a treatment for COVID-19 would take place outside the U.S., and that the U.S. Defense Department would cease funding the company's late-stage studies for INO-4800.There are reallytwo issues at hand here. First, Inovio has fallen so far behind its peers due to the Food and Drug Administration's (FDA) partial clinical hold that it may not be able to carve out a meaningful percentage of global COVID-19 vaccine sales, even if INO-4800 is successful in clinical studies.Secondly, Inovio has nothing to show for itself after more than four decades. In spite of plenty of ongoing research, none of the company's experimental treatments have ever been approved by the FDA. That's a pretty glaring red flag.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":1978,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/377581011"}